1. Solanezumab in‐depth outcomes
- Author
-
Roger Clarnette, Ivonne Z. Jimenez-Velazquez, Ghulam M. Surti, Suman Jayadev, Anne M. Fagan, Clifford R. Jack, Peter J. Snyder, Christopher H. van Dyck, Erik D. Roberson, Guoqiao Wang, Mario Masellis, David B. Clifford, Chengjie Xiong, Randall J. Bateman, Jérémie Pariente, Tammie L.S. Benzinger, Ging-Yuek Robin Hsiung, Serge Gauthier, Rachelle S. Doody, Paul Delmar, Didier Hannequin, Doug R. Galasko, Sarah B. Berman, Florence Pasquier, Robert A. Koeppe, James J. Lah, Carlos Cruchaga, Paulo Fontoura, Alison Goate, Eric McDade, Raquel Sánchez-Valle, David Wallon, Dian‐Tu Study Team, Catherine J. Mummery, Colin L. Masters, Jared R. Brosch, Maïté Formaglio, B. Joy Snider, Susan Mills, Monika Baudler, Lawrence S. Honig, Bruno Dubois, John C. Morris, Kelley Coalier, Brian A. Gordon, Stephen Salloway, Andrew J. Aschenbrenner, Jason Hassenstab, Anna Santacruz, William S. Brooks, Geoffrey A. Kerchner, and Martin R. Farlow
- Subjects
Oncology ,medicine.medical_specialty ,Epidemiology ,business.industry ,Health Policy ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Internal medicine ,medicine ,Neurology (clinical) ,Solanezumab ,Geriatrics and Gerontology ,business ,Gantenerumab ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF